Effect of GP IIb/IIIa inhibitor duration on the clinical prognosis of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction with no-/slow-reflow phenomenon-Reference-Cited by-同舟云学术

Effect of GP IIb/IIIa inhibitor duration on the clinical prognosis of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction with no-/slow-reflow phenomenon

Published:2021-11 Issue: Volume:143 Page:112196
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Hu Xiangming,Wang Weimian,Ye Jingguang,Lin Yan,Yu Bingyan,Zhou Langping,Zhou Yingling,Dong Haojian

Funder

Guangdong Provincial People's Hospital

National Key Research and Development Program of China

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference39 articles.

1. No-reflow phenomenon following coronary angioplasty - a review of mechanisms and therapies;Dabrowski;Kardiol. Pol.,2002

2. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory;Rezkalla;Catheter Cardiovasc Inter.,2008

3. Predictors of no-reflow phenomenon in young patients with acute st-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention;Celik;Angiology,2016

4. REstoration of COronary flow in patients with no-reflow after primary coronary interVEntion of acute myocaRdial infarction (RECOVER);Huang;Am. Heart J.,2012

5. Reduction of no reflow with a loading dose of atorvastatin before primary angioplasty in patients with acute ST myocardial infarction;Garcia-Mendez;Arch. Med. Res.,2018

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Smoking paradox in coronary function and structure of acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention;BMC Cardiovascular Disorders;2024-08-14

2. Epidemiology and current management of cardiovascular disease in China;Journal of Geriatric Cardiology;2024-04

3. Efficacy and safety of intracoronary versus intravenous tirofiban in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A meta-analysis of randomized controlled trials;Heliyon;2023-05

4. Aspirin/tirofiban;Reactions Weekly;2022-10-29